Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS9 | O00182 | 1/20 | 0.43 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.43 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC43A1 | O75387 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25504933 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL29323260 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL25504875 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL25524899 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL10024720 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL17322467 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL16769132 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL17211042 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL25504930 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL25504609 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207299-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES FOR TREATING OR PREVENTING A SARS-COV-2 INFECTION | CHIMERIX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-03-22 | — | — | US | disclosed |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2018-02-15 | — | — | US | disclosed |
| US-9862743-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170253628-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2017-09-07 | — | — | US | disclosed |
| US-9708359-B2 | Pyrrolopyrimidine nucleosides and analogs thereof | CHIMERIX, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9243022-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20160016987-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
| US-20150366887-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
| US-9186369-B2 | Purine nucleoside analogues for treating flaviviridae including hepatitis C | IDENIX PHARMACEUTICALS, LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-04-16 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
| US-20140234251-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | INDENIX PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | LGALS9 2942/4885LGALS1 3770/4885LGALS3 3839/4885 |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | LGALS9 2942/4885LGALS1 3770/4885LGALS3 3839/4885 |
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | LGALS9 4442/4885LGALS1 4678/4885LGALS3 4686/4885 |
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | LGALS9 2333/4885LGALS1 2852/4885LGALS3 3026/4885 |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | LGALS9 2701/4885LGALS1 3492/4885LGALS3 3708/4885 |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | LGALS9 3274/4885LGALS1 3748/4885LGALS3 3882/4885 |
| US-20140234251-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | PNP, TPMT, MTAP | LGALS9 2202/4885LGALS1 1550/4885LGALS3 1806/4885 |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | LGALS9 4442/4885LGALS1 4678/4885LGALS3 4686/4885 |
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | LGALS9 3274/4885LGALS1 3748/4885LGALS3 3882/4885 |
| US-20160016987-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | LGALS9 2942/4885LGALS1 3770/4885LGALS3 3839/4885 |
| US-20150366887-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | LGALS9 3153/4885LGALS1 3862/4885LGALS3 3935/4885 |
| US-20170253628-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | TYMP, PNP, DPYD | LGALS9 2461/4885LGALS1 3001/4885LGALS3 3860/4885 |
| US-20240207299-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES FOR TREATING OR PREVENTING A SARS-COV-2 INFECTION | PNP, ACE2, TYMP | LGALS9 1646/4885LGALS1 2256/4885LGALS3 3408/4885 |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | LGALS9 2701/4885LGALS1 3492/4885LGALS3 3708/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | LGALS9 3540/4885LGALS1 2797/4885LGALS3 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.